Your browser is no longer supported. Please, upgrade your browser.
EMMA Emmaus Life Sciences, Inc. daily Stock Chart
Emmaus Life Sciences, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own- Shs Outstand47.47M Perf Week-13.31%
Market Cap132.91M Forward P/E- EPS next Y-4.62 Insider Trans- Shs Float5.40M Perf Month-17.65%
Income- PEG- EPS next Q-1.32 Inst Own- Short Float0.76% Perf Quarter-62.96%
Sales22.90M P/S5.80 EPS this Y43.50% Inst Trans- Short Ratio0.36 Perf Half Y-70.87%
Book/sh-1.01 P/B- EPS next Y26.70% ROA- Target Price28.50 Perf Year-77.78%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.49 - 12.91 Perf YTD-36.25%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.31% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.45% ATR0.56
Employees28 Current Ratio- Sales Q/Q128.30% Oper. Margin- RSI (14)39.20 Volatility18.15% 14.55%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.54 Prev Close2.80
ShortableYes LT Debt/Eq- EarningsAug 19 Payout- Avg Volume114.39K Price2.80
Recom2.00 SMA20-17.89% SMA50-41.13% SMA200-61.08% Volume0 Change0.00%
Sep-18-19 10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks -8.79%
07:00AM  Emmaus Life Sciences Huddles Up with SCDAAMI to Host "Sideline Sickle Cell" Community Town Hall in Detroit PR Newswire
Sep-16-19 10:29AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks
Sep-10-19 08:00AM  Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing PR Newswire -38.31%
Sep-06-19 07:15PM  Emmaus Life Sciences Inc (EMMA) Chairman and CEO Yutaka Niihara Bought $130,971 of Shares
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks
08:30AM  Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis PR Newswire
Sep-02-19 09:17AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks
Aug-28-19 02:16PM  Emmaus Life Sciences Adds Oncology Supply as Distributor PR Newswire +9.47%
Aug-21-19 07:15PM  Emmaus Life Sciences Inc (EMMA) Chairman and CEO Yutaka Niihara Bought $65,910 of Shares
Aug-14-19 07:00AM  Emmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South Florida PR Newswire -12.47%
Aug-12-19 08:00AM  Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial Results PR Newswire +6.10%
Aug-08-19 03:51PM  Emmaus Life Sciences Reiterates Financial Benefits from Recent Merger PR Newswire -13.32%
Jul-29-19 08:00AM  Emmaus Life Sciences Details Financial Benefits from Recent Merger, including Improved Balance Sheet and Reduced Debt Service PR Newswire
Jul-22-19 04:05PM  Emmaus Life Sciences Receives Notice of Nasdaq Delisting Following Merger with MYnd Analytics PR Newswire -14.72%
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.